Company Analysis
Sign in

Trinity Biotech plc (TRIB)

Nasdaq: TRIB · In Vitro & In Vivo Diagnostic Substances · filing with the SEC since 1996
Full chart Alerts Compare
Grade4.1
◀ Past 4.1● Present 3.6▶ Future 4.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2024, as filed
Revenue$61.6M+8.3%
Net income-$31.2M+15.3%
Earnings per sharen/a
Operating cash flow-$4.2M+63.7%
Cash$5.2M+40.0%
Debtn/a
Shareholders’ equity-$35.2M-46.9%
Shares, diluted359.2M+134.6%
Return on equityn/a
The recordfrom its filings
Filings in 202669
Newest filingNov 12 · 6-K
Annual reportApr 30, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
15161718192021222324
As filed, in USD. Nothing here is a forecast.

News

Sep 1, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton TRIB · research, not advice